Je li PRA Health Sciences dividenda sigurna?
PRA Health Sciences povećava dividendu već 0 godina.
U posljednjih 10 godina, PRA Health Sciences je ovo povećao/povećala za godišnjih 0 % snižen.
Na petogodišnjoj razini pao isplata se povećala za 0 %.
Analitičari za tekuću poslovnu godinu očekuju rast od Smanjenje dividende% na −100,000%.
PRA Health Sciences Aktienanalyse
Što radi PRA Health Sciences?
PRA Health Sciences Inc. is a globally operating company for clinical research that was founded in 1982 and is headquartered in Raleigh, North Carolina. It specializes in supporting pharmaceutical and medical device manufacturers in the development and approval of drugs and medical devices.
The business model of PRA Health Sciences is based on providing services throughout the entire clinical development process. This includes planning and conducting clinical trials, monitoring study centers, data collection and management, as well as statistics and medical consulting.
The company's activities are divided into several divisions that focus on different areas of clinical development. The "Early Development Services" division offers services for the early clinical development of drugs and medical devices, including the conduct of Phase I studies and support for proof-of-concept studies. The "Clinical Development Services" division offers services for the later clinical development of drugs and medical devices, including the conduct of Phase II to Phase IV studies.
The "Strategic Solutions" division offers a wide range of services for the entire clinical development process, including consulting, data analysis and interpretation, as well as the integration of technologies such as electronic medical records software. The "Product Registration" division offers services for the approval of drugs and medical devices, including support for submission of applications and the provision of regulatory affairs consulting services.
One of the products offered by PRA Health Sciences is the "Lifetree Clinical Research" software platform, which is used for the management of clinical trials. Lifetree offers features for data management, project collaboration, and reporting, allowing users to access extensive amounts of data in real-time.
PRA Health Sciences has a broad customer base including pharmaceutical and biotech companies, medical device manufacturers, and contract research organizations. The company has offices in more than 80 countries and employs approximately 18,000 people worldwide.
In 2020, PRA Health Sciences was acquired by ICON plc, another globally operating company for clinical research. The acquisition is intended to expand ICON's global presence and service areas, enabling the company to offer a broader range of services in clinical development to its clients.
Overall, PRA Health Sciences is a company for clinical research that offers a wide range of services for the development of drugs and medical devices. With its broad customer base, comprehensive range of services, and global presence, it is an important component of the clinical research industry and is expected to continue to play a crucial role in the development of new drugs and medical devices. PRA Health Sciences je jedna od najpopularnijih kompanija na Eulerpool.com.Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.